Pitolisant for Sleepiness When CPAP Is Not Used

Pitolisant has different approved uses across countries. US Wakix labeling covers narcolepsy, not obstructive sleep apnea.¹²

Trial results

HAROSA II randomized 268 adults with moderate-to-severe sleep apnea and excessive sleepiness who refused or could not tolerate continuous positive airway pressure (CPAP); 75% were men. They received clinician-titrated daily pitolisant or placebo for twelve weeks.³

The self-rated Epworth Sleepiness Scale, measuring dozing propensity, improved by 2.8 points more with pitolisant (95% confidence interval 1.5–4.0). The laboratory Oxford Sleep Resistance Test did not show a statistically significant wakefulness benefit. Missing final scores used previous observations. Bioprojet funded the study; authors included company employees.³

Later, HAROSA III randomized 361 CPAP users and nonusers and reported lower self-rated sleepiness and longer laboratory wakefulness times. Its flexible dosing did not randomly compare higher with lower doses.⁴

Ask the sleep specialist which outcome matters for your day. A change on a questionnaire and a change during a laboratory test answer different questions; neither is a driving-clearance certificate.

Prescription boundaries

European Ozawade is indicated for adult apnea-related sleepiness not satisfactorily treated by, or when patients cannot tolerate, primary apnea therapy. Its product information explicitly says it does not treat the airway obstruction; primary treatment should continue or be periodically retried.²

The US label warns of QT prolongation, a heart-rhythm risk. Severe liver impairment and allergy are contraindications. Kidney or liver impairment and interacting medicines can change dosing or monitoring. Seek immediate medical advice for faintness, loss of consciousness or palpitations. Hormonal contraceptives may be less effective: an alternative nonhormonal method is advised during treatment and for at least 21 days afterward. Discuss pregnancy and breastfeeding with the prescriber.¹

Take the exact product name and your medication list to the pharmacist. Do not translate a dose printed in a research paper into tablets from another country.

Continuing apnea care

NICE⁵ recommends CPAP for moderate or severe apnea. For adults unable to tolerate or declining CPAP, a customized or semi-customized jaw-advancing splint can be considered when dental and gum health are suitable.⁵

Ask which alternatives are appropriate for your airway and how their effect will be checked. A medicine discussion should have an accompanying plan for the breathing disorder.

Did I Do That in My Sleep? includes “Other Options Have Specific Roles,” explaining why an apnea appliance differs from an ordinary tooth guard and needs qualified fitting and follow-up.